Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 116 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

116 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 116 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

116 programs

Clinical programs

Page 2 of 3

  1. HCV-001

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis B Vaccines

    approved mab completed

    1 trial

  2. Harvoni (Fixed dose combination ledipasvir/sofosbuvir)

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C

    approved small molecule completed

    1 trial

  3. Hydrocortisone Acetate 1% Ointment

    BRIGHT MINDS BIOSCIENCES INC.

    Postoperative Sore Throat, Cough, Hoarseness

    approved small molecule active

    1 trial

  4. IIV4 and PPV23

    BRIGHT MINDS BIOSCIENCES INC.

    Influenza, Human

    approved mab completed

    1 trial

  5. IRB202101979 -A

    BRIGHT MINDS BIOSCIENCES INC.

    Pneumonia

    approved small molecule terminated

    1 trial

  6. Injectable buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    approved small molecule active

    1 trial

  7. Intravenous fentanyl citrate

    BRIGHT MINDS BIOSCIENCES INC.

    Peer Review, Research

    approved small molecule completed

    1 trial

  8. Mailed nicotine replacement therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    approved small molecule completed

    1 trial

  9. Metformin

    BRIGHT MINDS BIOSCIENCES INC.

    Systemic Inflammation

    approved small molecule active

    1 trial

  10. Methadone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    approved small molecule completed

    1 trial

  11. Methadone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    approved small molecule active

    3 trials

  12. Methylphenidate

    BRIGHT MINDS BIOSCIENCES INC.

    Carboxylesterase 1 (CES1) Genotype

    approved small molecule completed

    2 trials

  13. Methylphenidate

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    approved small molecule completed

    3 trials

  14. Minocycline

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    approved small molecule completed

    1 trial

  15. Morphine

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Pain

    approved small molecule terminated

    1 trial

  16. Nicotine

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    approved small molecule completed

    1 trial

  17. Nicotine Nasal Spray

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    approved small molecule completed

    1 trial

  18. Nicotine Patch

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking

    approved small molecule completed

    3 trials

  19. Nicotine patch

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    approved small molecule terminated

    3 trials

  20. Nicotine patch - transdermal

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    approved small molecule completed

    1 trial

  21. OOPEN+BBCC

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Overdose

    approved small molecule completed

    1 trial

  22. Oral Methamphetamine

    BRIGHT MINDS BIOSCIENCES INC.

    HIV-1-infection

    approved small molecule completed

    1 trial

  23. Oral consumption

    BRIGHT MINDS BIOSCIENCES INC.

    Growth Acceleration

    approved other completed

    1 trial

  24. Oxycodone

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Low Back Pain

    approved small molecule completed

    1 trial

  25. Pegylated Interferon

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    approved small molecule completed

    1 trial

  26. Pfizer-BioNTech mRNA COVID-19 vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    COVID -19

    approved small molecule active

    1 trial

  27. Pharmacotherapy

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    approved small molecule completed

    1 trial

  28. Pharmacotherapy for opioid use disorder

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infection

    approved small molecule completed

    1 trial

  29. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    approved small molecule completed

    1 trial

  30. Progesterone

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    approved small molecule completed

    1 trial

  31. Prograf

    BRIGHT MINDS BIOSCIENCES INC.

    Renal Transplant Rejection

    approved small molecule completed

    1 trial

  32. Propranolol

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking

    approved small molecule completed

    1 trial

  33. Propranolol

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    approved small molecule active

    1 trial

  34. Quetiapine and placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Disorder

    approved small molecule completed

    1 trial

  35. Regional Anesthesia

    BRIGHT MINDS BIOSCIENCES INC.

    Inguinal Hernia

    approved small molecule completed

    1 trial

  36. Reinforcement Based Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    approved other completed

    1 trial

  37. Scheduled Gradual Reduction + Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Addiction

    approved other terminated

    1 trial

  38. Short Cycle Antiretroviral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    approved other completed

    1 trial

  39. Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]

    BRIGHT MINDS BIOSCIENCES INC.

    HEPATITIS C (HCV)

    approved small molecule active

    1 trial

  40. Sofosbuvir/velpatasvir (Epclusa®)

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C

    approved small molecule completed

    1 trial

  41. Stimulant or sedative

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    approved small molecule completed

    1 trial

  42. Thoracic epidural (ropivicaine, fentanyl)

    BRIGHT MINDS BIOSCIENCES INC.

    Pectus Excavatum

    approved small molecule completed

    1 trial

  43. Transdermal Nicotine Patch

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    approved small molecule terminated

    1 trial

  44. Transdermal nicotine patch

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    approved small molecule completed

    1 trial

  45. Vaccination to prevent hepatitis B virus infection

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis B

    approved mab completed

    1 trial

  46. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    approved small molecule completed

    2 trials

  47. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    approved small molecule completed

    3 trials

  48. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Parkinson's Disease

    approved small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

116 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.